Iovance Biotherapeutics (NASDAQ: IOVA) reported Q3 EPS of ($0.40), $0.01 worse than the analyst estimate of ($0.39).“We continue making great ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE